Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases

Tayade, Pralhad; Madhusudan, Saraf; Rajendrakumar, Kale

doi:10.1211/0022357021819

Cited by 58 publications

(42 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common side effects associated with anti-angiogenic therapy are hypertension and occasional bleeding along with impaired physiological angiogenesis such as wound healing, reproduction and fetal development [112–114]. These side effects limit the population of patients that can be treated and affect the dosing and scheduling of agents that are administered.…”

Section: Challenges Of Current Anti-angiogenic Therapiesmentioning

confidence: 99%

Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference

Biel

Siemann

2016

Cancer Letters

View full text Add to dashboard Cite

Anti-angiogenic therapies target the tumor vasculature, impairing its development and growth. It was hypothesized over 40 years ago by the late Judah Folkman and Julie Denekamp that depriving a tumor of oxygen and nutrients, by targeting the tumor vasculature, could have therapeutic benefits. Identification of growth factors and signaling pathways important in angiogenesis subsequently led to the development of a series of anti-angiogenic agents that over the past decade have become part of the standard of care in several disease settings. Unfortunately not all patients respond to the currently available anti-angiogenic therapies while others become resistant to these agents following prolonged exposure. Identification of new pathways that may drive angiogenesis led to the development of second-generation anti-angiogenic agents such as those targeting the Ang-2/Tie2 axis. Recently, it has become clear that combination of first and second generation agents targeting the blood vessel network can lead to outcomes superior to those using either agent alone. The present review focuses on the current status of VEGF and Ang-2 targeted agents and the potential utility of using them in combination to impair tumor angiogenesis.

show abstract

Section: Challenges Of Current Anti-angiogenic Therapiesmentioning

confidence: 99%

Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference

Biel

Siemann

2016

Cancer Letters

View full text Add to dashboard Cite

show abstract

“…During the tumor growth, neoangiogenesis is a critical step to supply cancer cells for nutrients and oxygen. In fact, tumor progression and of course metastasis or invasion are undeniably connected to angiogenesis [117]. How the angiogenesis starts, related to the tumor environment’s changes.…”

Section: Tumor-associated Endothelial Cells (Tecs)mentioning

confidence: 99%

“…As an example, tumor environment became hypoxic and metabolic pathways of tumor cells make it acidic. These are two of important signals that induce neoangiogenesis through VEGF signaling pathway [117]. Interestingly, there are some evidences showing that endothelial cells (ECs) and their related pericytes are morphologically and genetically different with normal one.…”

Section: Tumor-associated Endothelial Cells (Tecs)mentioning

confidence: 99%

Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy

Birgani

Carloni

2017

IJMS

147

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is among the most lethal and prevalent cancers in the human population. Different etiological factors such as hepatitis B and C virus, alcohol and diabetes cause liver injury followed by inflammation, necrosis and hepatocytes proliferation. Continuous cycles of this destructive–regenerative process culminates in liver cirrhosis which is characterized by regenerating nodules that progress to dysplastic nodules and ultimately HCC. Despite its significance, there is only an elemental understanding of the pathogenetic mechanisms, and there are only limited therapeutic options. Therefore, the study of the involved molecular mechanisms can open a new insight to define more effective treatment strategies. A variety of alterations have been reported in HCC patients, particularly the cancer-associated microenvironment components including immune cells, fibroblast cells, endothelial cells and extracellular matrix can support the neoplastic cells to proliferate, growth and invade. This review summarizes the current state of knowledge and highlights the principal challenges that are relevant to controlling this milieu.

show abstract

“…Several new therapeutic strategies [70, 71] are targeting pathologic vascularity and angiogenesis [72]. Some of these agents are currently completing phase I trials.…”

Section: Translating MI To Man—the Mr Approach In Oncologymentioning

confidence: 99%

Molecular imaging in oncology

Dzik-Jurasz¹

2004

Cancer Imaging

View full text Add to dashboard Cite

Cancer is a genetic disease that manifests in loss of normal cellular homeostatic mechanisms. The biology and therapeutic modulation of neoplasia occurs at the molecular level. An understanding of these molecular processes is therefore required to develop novel prognostic and early biomarkers of response. In addition to clinical applications, increased impetus for the development of such technologies has been catalysed by pharmaceutical companies investing in the development of molecular therapies. The discipline of molecular imaging therefore aims to image these important molecular processes in vivo. Molecular processes, however, operate at short length scales and concentrations typically beyond the resolution of clinical imaging. Solving these issues will be a challenge to imaging research. The successful implementations of molecular imaging in man will only be realised by the close co-operation amongst molecular biologists, chemists and the imaging scientists.

show abstract

Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases

Cited by 58 publications

References 64 publications

Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference

Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference

Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy

Molecular imaging in oncology

Contact Info

Product

Resources

About